FDA Grants Breakthrough Therapy Designation for Zovegalisib in Breast Cancer, Alongside Positive Q1 Updates
Summary
Relay Therapeutics announced that its lead candidate, zovegalisib, received FDA Breakthrough Therapy designation for PIK3CA-mutant, HR+/HER2- advanced breast cancer, a significant regulatory milestone. This designation, supported by robust clinical data, could expedite the drug's development and review process. The company also reported its first quarter 2026 financial results, ending the quarter with approximately $642 million in cash, cash equivalents, and investments, which supports its extended cash runway into 2029 as previously reported. Additionally, Relay initiated a Phase 1/2 trial for RLY-8161, an NRAS-selective inhibitor, expanding its pipeline. This news builds on the compelling clinical data for the zovegalisib triplet combination announced in late April, further validating the company's pipeline. Investors will be watching for initial clinical data for zovegalisib in vascular anomalies, expected on May 19, and the planned Phase 3 frontline breast cancer study initiation in early 2027.
At the time of this announcement, RLAY was trading at $12.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $2.67 to $17.32. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.